Metrics to compare | 388870 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship388870PeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.8x | −4.8x | −0.5x | |
PEG Ratio | 6.34 | 0.04 | 0.00 | |
Price/Book | 8.4x | 2.4x | 2.6x | |
Price / LTM Sales | - | 11.9x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 47.1% | |
Fair Value Upside | Unlock | 1.2% | 6.2% | Unlock |
Pharos iBio Co., Ltd. engages in the development of treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of recurrent ovarian cancer; PHI-501 for refractory solid cancer; PHI-301 for the treatment of refractory lung cancer; and PHI-601 for the treatment of menin inhibitor. The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.